Literature DB >> 11057971

Seroprevalence of HIV and HTLV in a representative sample of the Spanish population.

J Castilla1, I Pachón, M P González, C Amela, L Muñoz, O Tello, I Noguer, F de Ory, P León, M Alonso, E Gil, A García-Sáiz.   

Abstract

HIV and HTLV seroprevalence was determined by means of unlinked anonymous testing of 2144 sera, originally obtained from primary care patients by representative sampling of the Spanish population aged 15-39 years in 1996. HIV-1 seroprevalence was 4.3 per 1000 population in the 15-39 years age group [95% confidence interval (CI), 1.5-10.7] and 5.6 per 1000 (95% CI, 1.8-15.3) in the 20-39 years age group. Seroprevalence proved higher in males and urban residents. No antibodies to HIV-2 and HTLV-I were detected in any of the sera studied. However, presence of antibodies to HTLV-II was confirmed in one serum sample, while HTLV seroreactivity, though detected in another, could not be typed. The two HTLV-positive results equated to a seroprevalence of 1.9 per 1000 in the 20-39 years age group (95% CI, 0.3-8.6). HIV-I seroprevalence was consistent with previous estimates yielded by back-calculation. The level of HTLV seroprevalence found suggests endemicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057971      PMCID: PMC2869581          DOI: 10.1017/s0950268899004203

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Prevalence of HIV, HTLV-I and HTLV-II among female sex workers in Spain, 2000-2001.

Authors:  María José Belza
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  HIV infection among people of foreign origin voluntarily tested in Spain. A comparison with national subjects.

Authors:  Jesús Castilla; Paz Sobrino; Julia del Amo
Journal:  Sex Transm Infect       Date:  2002-08       Impact factor: 3.519

3.  Data quality assessment and subsampling strategies to correct distributional bias in prevalence studies.

Authors:  A D'Ambrosio; J Garlasco; F Quattrocolo; C Vicentini; C M Zotti
Journal:  BMC Med Res Methodol       Date:  2021-04-30       Impact factor: 4.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.